The most popular content from our Asembia coverage largely covered biosimilars.
While Asembia’s 2023 Specialty Pharmacy Summit covered a wide range of topics, including addressing health equity concerns within practices, updates on the specialty pharmacy pipeline, and policy discussions, biosimilars ultimately took center stage, according to the top content from The American Journal of Managed Care®’s Asembia coverage.
Here is the top coverage from Asembia, which was held April 30-May 4 in Las Vegas, Nevada, and check out all of our coverage.
5. How Are Health Care Organizations Working on DEI Efforts?
Inequitable care and health care deserts are well-known issues in the United States, and how to solve these health equity problems and improve internal diversity, equity, and inclusions initiatives were the main focus of this session from Asembia. Bansi Nagji, president of health care at GoodRx, gave a presentation on the topic, followed by a panel discussion, in which he was joined by Preeti Parikh, MD, practicing physician and executive medical director at GoodRx, and Pierre Theodore, MD, executive director of health equity at Genentech. The panel discussion covered what is currently being done and future focus.
4. Julie Reed: The Status Quo for Biosimilars Needs to Change to Maintain the Industry
Juliana (Julie) Reed, executive director of the Biosimilars Forum, discussed the challenges still facing the biosimilars industry and how they may impact the success of adalimumab biosimilars in the United States during a presentation at the meeting. She emphasized that biosimilars can play a role in addressing health equity issues since women, seniors, and low-income patients benefit the most from biosimilar competition. Reed also covered payer challenges that are limiting market competition and access to biosimilars.
3. An Overview of the Specialty Therapy Pipeline in 2023
The specialty pipeline has been growing year over year, and it’s projected to grow another 8% per year through 2025, noted Ray Tancredi, divisional vice president at Walgreens. In his presentation at Asembia, he highlighted 6 major trends in the specialty drug pipeline: innovation, gene and cell therapy, oncology therapies, patient centricity, biosimilars, and rare disease therapies.
2. Survey Shows Payers More Likely to Prefer Multiple Biosimilars for the Same Reference Product
During session, speakers reported that payers are more likely to prefer multiple biosimilars for the same reference product rather than just prefer 1 biosimilar or just the reference product. The presenters were Tasmina Hydery, PharmD, MBA, BCGP, associate director of digital solutions at AmerisourceBergen, and Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilars Collective Intelligence Consortium. They reviewed the current biosimilars landscape, discussed how payers view biosimilars at present and how biosimilars are being operationalized, and reviewed current pieces of legislation that are affecting biosimilar adoption.
1. Dr Fran Gregory Discusses the Implications of a New Wave of Biosimilars
During an interview at Asembia, Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discussed how biosimilars increase accessibility to medications for patients. She talked about the second wave of biosimilars, starting with the adalimumab biosimilars in 2023, hitting the market and the importance in the context of specialty pharmacy. It’ll be important for specialty pharmacies to understand the patient assistance programs and any financial support that is available for biosimilars as they did with many of these reference products, Gregory explained.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Health Equity and Access Weekly Roundup: May 11, 2024
May 11th 2024This week's topics include frameworks for improving health equity nationwide, addressing social determinants of health, discussing CMS's Medicare rules, investigating breast cancer treatment refusal, and exploring HIV and major depressive disorder in underrepresented groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
Health Equity, Accessibility Essential to Supporting Women Affected by Hemophilia
May 10th 2024Due to often being overlooked as only carriers of hemophilia, the review authors sought to highlight the needs of female caretakers for patients with the disorder and the possibility of women themselves being affected by it.
Read More